VAXCYTE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 116.00 USD | +1.64% |
|
+3.96% | +84.71% |
| 10/09 | Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree... |  |
| 10/09 | Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating | MT |
Company Valuation: Vaxcyte, Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,354 | 1,256 | 3,787 | 5,976 | 14,349 | - | - |
| Change | - | -7.24% | 201.58% | 57.79% | 140.12% | - | - |
| Enterprise Value (EV) | 1,354 | 1,256 | 3,787 | 5,976 | 14,349 | 14,349 | 14,349 |
| Change | - | -7.24% | 201.58% | 57.79% | 140.12% | 0% | 0% |
| P/E ratio | -8.8x | -12.3x | -13.9x | -15.2x | -25.9x | -23.1x | -23.3x |
| PBR | - | - | - | - | - | - | - |
| PEG | 0.1x | 0.3x | -0.2x | -0.7x | -3.14x | -1.9x | 41.86x |
| Capitalization / Revenue | - | - | - | - | - | - | 670x |
| EV / Revenue | - | - | - | - | - | - | 670x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -29.9x | -29.6x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -25x | -22.9x | -22.9x |
| EV / FCF | - | -0x | -0x | -0x | -27.4x | -30.9x | -29.3x |
| FCF Yield | - | -10.2% | -1.75% | -5.24% | -3.65% | -3.24% | -3.41% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -3.02 | -1.93 | -3.44 | -4.14 | -4.481 | -5.016 | -4.988 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | 21.43 |
| EBITDA 1 | -88.18 | -101.9 | -229.7 | -464.9 | -480.1 | -484 | - |
| EBIT 1 | -89.58 | -103.7 | -232.3 | -468 | -573.7 | -625.9 | -627.6 |
| Net income 1 | -89.22 | -100.1 | -223.5 | -402.3 | -512.4 | -597 | -610.4 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 26.57 | 23.79 | 47.95 | 62.80 | 116.00 | 116.00 | 116.00 |
| Nbr of stocks (in thousands) | 50,950 | 52,785 | 78,980 | 95,154 | 1,23,697 | - | - |
| Announcement Date | 29/03/21 | 28/02/22 | 27/02/23 | 27/02/24 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E ratio | EV / Sales | EV / EBITDA | Yield (Y) | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -25.89x | - | - | -.--% | 14.35B | ||
| -244.92x | 10.73x | 141.27x | -.--% | 125B | ||
| 30.95x | 8.15x | 19.85x | -.--% | 124B | ||
| -529.73x | 14.58x | -177.05x | -.--% | 32.35B | ||
| -50.33x | 5.09x | -14.66x | -.--% | 29.34B | ||
| -32.6x | 5.35x | -32.91x | -.--% | 21.1B | ||
| 21.82x | 4.31x | 14.13x | -.--% | 16.98B | ||
| 12.13x | 2.65x | 7.51x | +2.42% | 16.01B | ||
| -14.37x | 37.48x | -17.48x | -.--% | 12.83B | ||
| Average | -92.55x | 11.04x | -7.42x | +0.27% | 43.64B | |
| Weighted average by Cap. | -117.44x | 9.75x | 35.55x | +0.10% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- PCVX Stock
- Valuation Vaxcyte, Inc.
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition